These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17565424)

  • 21. The pathogenic A391E mutation in FGFR3 induces a structural change in the transmembrane domain dimer.
    Mudumbi KC; Julius A; Herrmann J; Li E
    J Membr Biol; 2013 Jun; 246(6):487-93. PubMed ID: 23727984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FGFR3 unliganded dimer stabilization by the juxtamembrane domain.
    Sarabipour S; Hristova K
    J Mol Biol; 2015 Apr; 427(8):1705-14. PubMed ID: 25688803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strong dimerization of wild-type ErbB2/Neu transmembrane domain and the oncogenic Val664Glu mutant in mammalian plasma membranes.
    Placone J; He L; Del Piccolo N; Hristova K
    Biochim Biophys Acta; 2014 Sep; 1838(9):2326-30. PubMed ID: 24631664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence for new homotypic and heterotypic interactions between transmembrane helices of proteins involved in receptor tyrosine kinase and neuropilin signaling.
    Sawma P; Roth L; Blanchard C; Bagnard D; Crémel G; Bouveret E; Duneau JP; Sturgis JN; Hubert P
    J Mol Biol; 2014 Dec; 426(24):4099-4111. PubMed ID: 25315821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hill coefficient analysis of transmembrane helix dimerization.
    Soong R; Merzlyakov M; Hristova K
    J Membr Biol; 2009 Jul; 230(1):49-55. PubMed ID: 19603128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transient dimerization and interaction with ERGIC-53 occur in the fibroblast growth factor receptor 3 early secretory pathway.
    Lievens PM; De Servi B; Garofalo S; Lunstrum GP; Horton WA; Liboi E
    Int J Biochem Cell Biol; 2008; 40(11):2649-59. PubMed ID: 18577465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bacterial Synthesis and Purification of Normal and Mutant Forms of Human FGFR3 Transmembrane Segment.
    Goncharuk SA; Goncharuk MV; Mayzel ML; Lesovoy DM; Chupin VV; Bocharov EV; Arseniev AS; Kirpichnikov MP
    Acta Naturae; 2011 Jul; 3(3):77-84. PubMed ID: 22649697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure of FGFR3 transmembrane domain dimer: implications for signaling and human pathologies.
    Bocharov EV; Lesovoy DM; Goncharuk SA; Goncharuk MV; Hristova K; Arseniev AS
    Structure; 2013 Nov; 21(11):2087-93. PubMed ID: 24120763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
    Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
    Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-throughput selection of transmembrane sequences that enhance receptor tyrosine kinase activation.
    He L; Hoffmann AR; Serrano C; Hristova K; Wimley WC
    J Mol Biol; 2011 Sep; 412(1):43-54. PubMed ID: 21767549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple consequences of a single amino acid pathogenic RTK mutation: the A391E mutation in FGFR3.
    Chen F; Sarabipour S; Hristova K
    PLoS One; 2013; 8(2):e56521. PubMed ID: 23437153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of thanatophoric dysplasia type I mutations on FGFR3 dimerization.
    Del Piccolo N; Placone J; Hristova K
    Biophys J; 2015 Jan; 108(2):272-8. PubMed ID: 25606676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantifying the strength of heterointeractions among receptor tyrosine kinases from different subfamilies: Implications for cell signaling.
    Paul MD; Grubb HN; Hristova K
    J Biol Chem; 2020 Jul; 295(29):9917-9933. PubMed ID: 32467228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Forster resonance energy transfer in liposomes: measurements of transmembrane helix dimerization in the native bilayer environment.
    You M; Li E; Wimley WC; Hristova K
    Anal Biochem; 2005 May; 340(1):154-64. PubMed ID: 15802141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary and secondary dimer interfaces of the fibroblast growth factor receptor 3 transmembrane domain: characterization via multiscale molecular dynamics simulations.
    Reddy T; Manrique S; Buyan A; Hall BA; Chetwynd A; Sansom MS
    Biochemistry; 2014 Jan; 53(2):323-32. PubMed ID: 24397339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathogenic Cysteine Removal Mutations in FGFR Extracellular Domains Stabilize Receptor Dimers and Perturb the TM Dimer Structure.
    Sarabipour S; Hristova K
    J Mol Biol; 2016 Oct; 428(20):3903-3910. PubMed ID: 27596331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of the N-Terminal Transmembrane Helix Contacts in the Activation of FGFR3.
    Matsuoka D; Kamiya M; Sato T; Sugita Y
    J Comput Chem; 2020 Mar; 41(6):561-572. PubMed ID: 31804721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathogenic activation of receptor tyrosine kinases in mammalian membranes.
    He L; Hristova K
    J Mol Biol; 2008 Dec; 384(5):1130-42. PubMed ID: 18976668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
    Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
    Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization.
    Adar R; Monsonego-Ornan E; David P; Yayon A
    J Bone Miner Res; 2002 May; 17(5):860-8. PubMed ID: 12009017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.